Stargardt Disease Market to Witness Upsurge in Growth During the Forecast Period (2022-32), Examine DelveInsight | Nanoscope Therapeutics (MCO-010), Belite Bio (LBS-008), Fera (Phospholine Iodide)

October 11 19:12 2022
Stargardt Disease Market to Witness Upsurge in Growth During the Forecast Period (2022-32), Examine DelveInsight | Nanoscope Therapeutics (MCO-010), Belite Bio (LBS-008), Fera (Phospholine Iodide)
Delveinsight Business Research LLP
As per DelveInsight, the Stargardt Disease (STGD) market size shall grow during the forecast period owing to the rise in the geriatric population leading to a rise in the number of people with Stargardt conditions along with emerging therapies.

DelveInsight’s “Stargardt Disease (STGD) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Stargardt Disease Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Stargardt Disease market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Stargardt Disease Market

Stargardt Disease: An Overview

Stargardt disease (STGD) is a rare retinal disorder inherited in an autosomal recessive pattern. Decreased central vision due to loss of photoreceptors in the macula is the hallmark of Stargardt disease. It typically develops during childhood or adolescence, but the age of onset and rate of progression can vary.

Currently, there is no treatment for Stargardt disease. Some ophthalmologists encourage people with Stargardt disease to wear dark glasses and hats when out in bright light to reduce the buildup of lipofuscin. Cigarette smoking and secondhand smoke should be avoided. Animal studies suggest that high-dose vitamin A may increase lipofuscin accumulation and potentially accelerate vision loss. 

Stargardt Disease (STGD) Market Key Facts

  • According to the National Institute for Health, the reported prevalence of Stargardt disease is estimated to be 1 in 8,000 to 10,000 individuals.

  • According to the American Institute of Ophthalmology, STGD is the most commonly inherited childhood and adulthood maculopathy and has a prevalence of 1 in 10,000.

  • According to the Foundation Fighting Blindness, Stargardt disease is the most common form of inherited macular degeneration, affecting about 30,000 people in the US.  

Stargardt Disease (STGD) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Stargardt Disease market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Stargardt Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Stargardt Disease (STGD) Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

Stargardt Disease (STGD) Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Stargardt Disease market or expected to get launched during the study period. The analysis covers Stargardt Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Stargardt Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Recent Developments in the Stargardt Disease (STGD) Therapeutics Market 

  • On September 13, 2022, Nanoscope Therapeutics announced full enrollment of its Phase 2 clinical trial of MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic monotherapy to restore vision in blind patients for Stargardt disease. 

  • On July 19, 2022, Belite Bio announced the submission of an Investigational New Drug (IND) application to the US FDA to support the Phase 3 development of LBS-008. Belite’s LBS-008 is an orally administered treatment for Stargardt Disease.

  • On April 12, 2022, Fera Pharmaceuticals announced that FDA had granted Orphan Drug Designation for Phospholine Iodide (echothiophate iodide for ophthalmic solution) as a treatment for Stargardt disease.

Learn How Stargardt Disease Market Will Evolve by 2032 @

Stargardt Disease (STGD) Therapeutics Analysis

Research is underway to identify novel treatment approaches that may prove to be a way to support patients affected with Stargardt Disease (STGD). Some of the key players at the global level are involved in developing therapies for Stargardt’s disease. The launch of emerging therapies is expected to immensely transform the treatment outlook in the coming years.

Some of the key companies in the Stargardt Disease (STGD) therapeutics market include:

  • Acucela Inc (Kubota)

  • Alkeus Pharmaceuticals Inc

  • ProQR

  • Astellas Pharma Inc 

And others

Stargardt Disease (STGD) Therapies Covered in the Report Include:

  • Emixustat

  • ALK-001

  • QR-1011

  • ASP7317

And many more. 

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More:

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Stargardt Disease Competitive Intelligence Analysis

4. Stargardt Disease Market Overview at a Glance

5. Stargardt Disease Disease Background and Overview

6. Stargardt Disease Patient Journey

7. Stargardt Disease Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Stargardt Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Stargardt Disease Unmet Needs

10. Key Endpoints of Stargardt Disease Treatment

11. Stargardt Disease Marketed Products

12. Stargardt Disease Emerging Drugs and Latest Therapeutic Advances

13. Stargardt Disease Seven Major Market Analysis

14. Attribute Analysis

15. Stargardt Disease Market Outlook (In US, EU5, and Japan)

16. Stargardt Disease Access and Reimbursement Overview

17. KOL Views on the Stargardt Disease Market

18. Stargardt Disease Market Drivers

19. Stargardt Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight 

Carpal Tunnel Release System Market

“Carpal Tunnel Release System Market” research report provides comprehensive insights into the historic and forecasted market size, share, trends, and growth estimation for the Carpal Tunnel Release System. It also covers the latest breakthroughs, collaboration, latest innovations, emerging devices, and key companies working in the global Carpal Tunnel Release System market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States